Immunai
New York City, US · 7 known investors
Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.
Investors · 7
Acquisitions · 1
Early investors' stakes continue via these dealsDropprint Genomics
Dropprint Genomics develops software for analyzing individual cell activity in genomic data, serving researchers in immunology and drug discovery. The company reduces the cost and computational complexity of single-cell sequencing and maintains a database of over 1 million immune cells to support target identification using machine learning models.
In the news
- Miles Wang leaves OpenAI for a $2bn AI drug startupthenextweb.com · 2026
- Immunai uses AI to hunt for cancer, autoimmune targets in $15M Boehringer dealynetnews.com · 2026
- Israeli-founded AI biotech Immunai launches drug-discovery collaboration with Boehringer Ingelheimjpost.com · 2026
- Immunai signs up to $15 million research pact with Boehringer Ingelheim | Ctechcalcalistech.com · 2026
- BioCentury - Oct. 27 Quick Takes: Advancing ‘atlas’ of immunology, Immunai raises $215Mbiocentury.com · 2021
- U.S.-Israeli biotech startup Immunai raises $20 million | Reutersreuters.com · 2020